絞り込み

16603

広告

Evaluation of the VeriStrat(®) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

著者 Gadgeel S , Goss G , Soria JC , Felip E , Georgoulias V , Lu S , Cobo M , Syrigos K , Lee KH , Göker E , Guclu SZ , Isla D , Morabito A , Dupuis N , Bühnemann C , Krämer N , Solca F , Ehrnrooth E , Ardizzoni A
Lung Cancer.2017 Jul ; 109():101-108.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (126view , 0users)

Full Text Sources

Medical

Miscellaneous

Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after first-line chemotherapy. In this study, the ability of the VeriStrat serum protein test to predict differential clinical benefit with afatinib versus erlotinib, and the association of VeriStrat status with clinical outcomes irrespective of EGFR-TKI used, was assessed in a retrospective analysis of the phase III LUX-Lung 8 trial.
PMID: 28577938 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード